FindTrial
Sign In

Study to Understand the effects of Glimepiride, Dapagliflozin and Metformin Combination Tablets in Indian Diabetic Patients

A retrospective multicenter observational study to assess the effectiveness and tolerability of fixed dose combination of glimepiride, dapagliflozin and metformin in type 2 Diabetes mellitus in Indian patients (UMBRELLA-2) - UMBRELLA-2

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/101076
Enrollment
25000
Registered
2026-01-14
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E11- Type 2 diabetes mellitus

Interventions

Intervention1: Nil: Nil

Sponsors

Torrent Pharmaceuticals Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who were prescribed FDC of Glimepiride, Dapagliflozin, Metformin ER (any dosage)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
1. Change in HbA1c over different time periodsTimepoint: Baseline and post 3 months—

Secondary

MeasureTime frame
1. Change in FPG, PPPG and body weightTimepoint: Baseline and post 3 months;2. Safety and tolerabilityTimepoint: Post 3 months—

Countries

India

Contacts

Public ContactNarendra Chouksey

Torrent Pharmaceuticals Ltd.

LokeshRV@torrentpharma.com917069000601

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026